Analysis Tools
endocrine/exocrine glands
 |
• mice treated with doxycycline for 2 weeks exhibit increased lateral branching and ductal ectasia of adult mammary ductal trees
|
|
|
• doxycycline treatment beginning at 8 weeks of age results in the development of mammary tumors with 100% penetrance and median latency of about 2 months
• tumors are consistent with moderate to poorly differentiated adenocarcinoma admixed with foci of ductal carcinoma in situ resembling human HER2-positive breast cancers
• tumor cell apoptosis and reduced tumor cellularity are seen within 24-48 hours of doxycycline removal, followed by tumor regression within 4-5 days
• lapatinib treatment results in arrest of tumor growth and/or regression
• about 2/3 of mice develop a recurrent mammary gland tumor when doxycycline is withdrawn; recurrent tumors do not express ERBB2 and have different expression profiles than primary tumors
• trastuzumab treatment results in in tumor regression and subsequent regrowth in two tumors despite continued therapy, indicating development of trastuzumab-resistant tumors
• primary tumor cells treated with both lapatinib and trastuzumab exhibit some growth inhibition which is enhanced further with the addition of the CDK4/6 inhibitor abemaciclib
|
integument
|
|
• mice treated with doxycycline for 2 weeks exhibit increased lateral branching and ductal ectasia of adult mammary ductal trees
|
|
|
• tumor cell apoptosis and reduced tumor cellularity are seen within 24-48 hours of doxycycline removal, followed by tumor regression within 4-5 days
• lapatinib treatment results in arrest of tumor growth and/or regression
• doxycycline treatment beginning at 8 weeks of age results in the development of mammary tumors with 100% penetrance and median latency of about 2 months
• tumors are consistent with moderate to poorly differentiated adenocarcinoma admixed with foci of ductal carcinoma in situ resembling human HER2-positive breast cancers
• about 2/3 of mice develop a recurrent mammary gland tumor when doxycycline is withdrawn; recurrent tumors do not express ERBB2 and have different expression profiles than primary tumors
• trastuzumab treatment results in in tumor regression and subsequent regrowth in two tumors despite continued therapy, indicating development of trastuzumab-resistant tumors
• primary tumor cells treated with both lapatinib and trastuzumab exhibit some growth inhibition which is enhanced further with the addition of the CDK4/6 inhibitor abemaciclib
|
neoplasm
|
|
• doxycycline treatment beginning at 8 weeks of age results in the development of mammary tumors with 100% penetrance and median latency of about 2 months
• tumors are consistent with moderate to poorly differentiated adenocarcinoma admixed with foci of ductal carcinoma in situ resembling human HER2-positive breast cancers
• tumor cell apoptosis and reduced tumor cellularity are seen within 24-48 hours of doxycycline removal, followed by tumor regression within 4-5 days
• lapatinib treatment results in arrest of tumor growth and/or regression
• about 2/3 of mice develop a recurrent mammary gland tumor when doxycycline is withdrawn; recurrent tumors do not express ERBB2 and have different expression profiles than primary tumors
• trastuzumab treatment results in in tumor regression and subsequent regrowth in two tumors despite continued therapy, indicating development of trastuzumab-resistant tumors
• primary tumor cells treated with both lapatinib and trastuzumab exhibit some growth inhibition which is enhanced further with the addition of the CDK4/6 inhibitor abemaciclib
|
|
|
• 80% of mice show lung metastases after 16 weeks of sustained doxycycline induction
• lung metastases are seen in only 15% of mice induced for 16 weeks and subsequently maintained on a doxycycline-free diet for 4 weeks
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
| breast cancer | DOID:1612 |
OMIM:114480 |
J:231766 | |
